Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

RELEASE DATE
12-Aug-2021
REGION
North America
Research Code: MG1B-01-00-00-00
SKU: HC03437-GL-MR_25633
$4,950.00
In stock
SKU
HC03437-GL-MR_25633
$4,950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPT’s debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving accuracy and positive predictive value. Frost & Sullivan forecasts a quadruple increase in penetration for average-risk pregnancies in 2021. Scalable, automated in-lab workflow solutions and remote patient monitoring in pregnancy will effectively address the incoming volume and improve overall test economics. A significant proportion of consolidation is focused on the distribution and marketing of NIPTs to expand access and coverage, followed by product development and commercialization agreements. Frost & Sullivan envisages the trend in consolidation to increase in the coming age of distributable kits, offering new solutions to drive the expansion of testing to all autosomes and microdeletions. As the clinical application becomes widespread, major leaps forward are on the horizon, including sequencing-free optics-based technology and approaches that analyze whole-fetal cells instead of cfDNA. Expanded clinical application of NIPT will accelerate technological developments in the field, making the sector a viable market.

Author: Amartya Bose

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Strategic Imperative

Strategic Imperative (continued)

Strategic Imperative (continued)

Growth Environment

Growth Environment (continued)

Growth Environment (continued)

Frost Radar™: Non-Invasive Prenatal Testing Market, Global, 2021

Frost Radar™: Competitive Environment

Frost Radar™: Competitive Environment (continued)

Natera, Inc.

Illumina, Inc.

LabCorp

BGI Genomics Co., Ltd

Roche

Yourgene Health Plc.

Quest Diagnostics

Eurofins Scientific (GeneTech)

PerkinElmer, Inc.

Cradle Genomics

Strategic Insights

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential

Frost Radar™: Benchmarking Future Growth Potential

Legal Disclaimer

Related Research
Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving accuracy and positive predictive value. Frost & Sullivan forecasts a quadruple increase in penetration for average-risk pregnancies in 2021. Scalable, automated in-lab workflow solutions and remote patient monitoring in pregnancy will effectively address the incoming volume and improve overall test economics. A significant proportion of consolidation is focused on the distribution and marketing of NIPTs to expand access and coverage, followed by product development and commercialization agreements. Frost & Sullivan envisages the trend in consolidation to increase in the coming age of distributable kits, offering new solutions to drive the expansion of testing to all autosomes and microdeletions. As the clinical application becomes widespread, major leaps forward are on the horizon, including sequencing-free optics-based technology and approaches that analyze whole-fetal cells instead of cfDNA. Expanded clinical application of NIPT will accelerate technological developments in the field, making the sector a viable market. Author: Amartya Bose
More Information
No Index No
Podcast No
Author Amartya Bose
Industries Healthcare
WIP Number MG1B-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9562-B1,9573-B1,99C6-B1,9627-B1